 Jonathan Gutman
Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cord Blood Stem Cell Transplantation | 20 | 2024 | 99 | 6.100 |
Why?
| | Hematopoietic Stem Cell Transplantation | 23 | 2025 | 614 | 5.720 |
Why?
| | Leukemia, Myeloid, Acute | 25 | 2024 | 620 | 4.930 |
Why?
| | Graft vs Host Disease | 15 | 2024 | 249 | 4.190 |
Why?
| | Transplantation Conditioning | 16 | 2024 | 170 | 3.300 |
Why?
| | Azacitidine | 10 | 2024 | 141 | 2.420 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 12 | 2024 | 228 | 1.890 |
Why?
| | Sulfonamides | 11 | 2024 | 513 | 1.490 |
Why?
| | Hematologic Neoplasms | 6 | 2021 | 158 | 1.260 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 22 | 0.890 |
Why?
| | Myelodysplastic Syndromes | 5 | 2019 | 135 | 0.840 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 11 | 0.840 |
Why?
| | Cytomegalovirus Infections | 3 | 2023 | 194 | 0.820 |
Why?
| | Fetal Blood | 6 | 2022 | 327 | 0.810 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1695 | 0.740 |
Why?
| | Recurrence | 10 | 2023 | 1060 | 0.740 |
Why?
| | Neoplasm, Residual | 5 | 2024 | 133 | 0.650 |
Why?
| | Leukemia | 5 | 2011 | 238 | 0.640 |
Why?
| | Graft Rejection | 4 | 2025 | 623 | 0.620 |
Why?
| | Transplantation, Homologous | 11 | 2023 | 416 | 0.600 |
Why?
| | Vancomycin | 1 | 2019 | 84 | 0.590 |
Why?
| | Thiotepa | 1 | 2018 | 20 | 0.590 |
Why?
| | Clostridium Infections | 1 | 2019 | 71 | 0.590 |
Why?
| | Pregnancy Complications | 1 | 2023 | 521 | 0.580 |
Why?
| | Retrospective Studies | 17 | 2025 | 15628 | 0.540 |
Why?
| | Humans | 74 | 2025 | 137514 | 0.510 |
Why?
| | Adult | 39 | 2025 | 37821 | 0.510 |
Why?
| | Antineoplastic Agents | 6 | 2020 | 2145 | 0.480 |
Why?
| | Middle Aged | 36 | 2025 | 33355 | 0.440 |
Why?
| | Stem Cell Transplantation | 4 | 2023 | 177 | 0.430 |
Why?
| | Carbon Monoxide | 1 | 2013 | 80 | 0.400 |
Why?
| | Aged | 26 | 2025 | 23798 | 0.390 |
Why?
| | Blood Banks | 2 | 2012 | 41 | 0.390 |
Why?
| | Young Adult | 16 | 2025 | 13243 | 0.380 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2012 | 15 | 0.380 |
Why?
| | Organ Transplantation | 2 | 2025 | 248 | 0.380 |
Why?
| | Blood Specimen Collection | 1 | 2011 | 38 | 0.360 |
Why?
| | Hematopoietic Stem Cells | 3 | 2015 | 398 | 0.360 |
Why?
| | HLA Antigens | 4 | 2019 | 237 | 0.350 |
Why?
| | Germ-Line Mutation | 1 | 2012 | 172 | 0.350 |
Why?
| | Female | 41 | 2025 | 73162 | 0.350 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2017 | 252 | 0.340 |
Why?
| | Hemoglobins | 1 | 2013 | 356 | 0.340 |
Why?
| | Lymphoma | 2 | 2017 | 207 | 0.340 |
Why?
| | Treatment Outcome | 15 | 2025 | 10821 | 0.340 |
Why?
| | Whole-Body Irradiation | 5 | 2019 | 78 | 0.330 |
Why?
| | Cesarean Section | 1 | 2011 | 187 | 0.320 |
Why?
| | Graft vs Leukemia Effect | 1 | 2009 | 12 | 0.320 |
Why?
| | Male | 41 | 2025 | 67718 | 0.310 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1800 | 0.300 |
Why?
| | Pulmonary Veno-Occlusive Disease | 1 | 2008 | 12 | 0.300 |
Why?
| | Isoantibodies | 1 | 2009 | 60 | 0.300 |
Why?
| | Immunotherapy, Adoptive | 2 | 2024 | 324 | 0.300 |
Why?
| | Neoplastic Stem Cells | 3 | 2018 | 398 | 0.290 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2023 | 1060 | 0.290 |
Why?
| | Disease-Free Survival | 4 | 2022 | 690 | 0.280 |
Why?
| | Rhinovirus | 1 | 2007 | 57 | 0.270 |
Why?
| | Picornaviridae Infections | 1 | 2007 | 46 | 0.270 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2013 | 121 | 0.260 |
Why?
| | Vidarabine | 2 | 2018 | 33 | 0.260 |
Why?
| | Clonal Evolution | 2 | 2017 | 45 | 0.250 |
Why?
| | Altitude Sickness | 4 | 2008 | 152 | 0.240 |
Why?
| | Adolescent | 14 | 2025 | 21555 | 0.240 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2020 | 806 | 0.240 |
Why?
| | Histocompatibility Testing | 3 | 2016 | 126 | 0.230 |
Why?
| | Chronic Disease | 3 | 2022 | 1790 | 0.230 |
Why?
| | Prognosis | 7 | 2024 | 4031 | 0.230 |
Why?
| | Mutation | 3 | 2024 | 3964 | 0.210 |
Why?
| | Antigens, CD19 | 1 | 2024 | 123 | 0.210 |
Why?
| | Immune Reconstitution | 1 | 2023 | 7 | 0.210 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2009 | 917 | 0.200 |
Why?
| | Altitude | 5 | 2007 | 482 | 0.200 |
Why?
| | Living Donors | 1 | 2005 | 295 | 0.200 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 395 | 0.200 |
Why?
| | Unrelated Donors | 3 | 2021 | 39 | 0.200 |
Why?
| | Pulmonary Edema | 3 | 2007 | 106 | 0.190 |
Why?
| | Carrier Proteins | 2 | 2017 | 770 | 0.190 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2017 | 807 | 0.180 |
Why?
| | Nuclear Proteins | 2 | 2017 | 710 | 0.180 |
Why?
| | Siblings | 1 | 2022 | 228 | 0.180 |
Why?
| | Chimerism | 1 | 2021 | 31 | 0.180 |
Why?
| | Salvage Therapy | 2 | 2019 | 143 | 0.180 |
Why?
| | Allografts | 1 | 2021 | 148 | 0.180 |
Why?
| | Myeloablative Agonists | 2 | 2018 | 22 | 0.170 |
Why?
| | Stem Cells | 2 | 2015 | 589 | 0.170 |
Why?
| | Autoimmune Diseases | 1 | 2024 | 459 | 0.170 |
Why?
| | Sirolimus | 2 | 2019 | 275 | 0.170 |
Why?
| | Antibodies, Monoclonal | 2 | 2017 | 1428 | 0.160 |
Why?
| | Survival Analysis | 3 | 2018 | 1320 | 0.160 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2019 | 17 | 0.160 |
Why?
| | Relaxation Therapy | 1 | 2019 | 18 | 0.160 |
Why?
| | Breathing Exercises | 1 | 2019 | 21 | 0.160 |
Why?
| | Leukocytes | 1 | 2021 | 311 | 0.160 |
Why?
| | Antiviral Agents | 3 | 2023 | 740 | 0.160 |
Why?
| | Acetates | 1 | 2019 | 100 | 0.150 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 219 | 0.150 |
Why?
| | Busulfan | 2 | 2020 | 16 | 0.150 |
Why?
| | Quality of Life | 2 | 2022 | 2870 | 0.150 |
Why?
| | Mountaineering | 3 | 2008 | 40 | 0.150 |
Why?
| | Fetus | 1 | 2023 | 807 | 0.150 |
Why?
| | Mycophenolic Acid | 1 | 2019 | 117 | 0.150 |
Why?
| | Quinazolines | 1 | 2019 | 249 | 0.140 |
Why?
| | Cyclosporine | 1 | 2019 | 268 | 0.140 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2013 | 292 | 0.140 |
Why?
| | Optic Nerve | 2 | 2008 | 64 | 0.140 |
Why?
| | Intracranial Pressure | 2 | 2008 | 47 | 0.140 |
Why?
| | Psychotherapy | 1 | 2019 | 165 | 0.140 |
Why?
| | Socioeconomic Factors | 1 | 2022 | 1286 | 0.140 |
Why?
| | Leukemia, Neutrophilic, Chronic | 1 | 2017 | 5 | 0.140 |
Why?
| | Receptors, Colony-Stimulating Factor | 1 | 2017 | 7 | 0.140 |
Why?
| | Child | 9 | 2025 | 22037 | 0.130 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 45 | 0.130 |
Why?
| | Administration, Oral | 1 | 2019 | 814 | 0.130 |
Why?
| | Risk Factors | 5 | 2025 | 10356 | 0.130 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 53 | 0.130 |
Why?
| | Immunosuppressive Agents | 2 | 2019 | 891 | 0.130 |
Why?
| | T-Lymphocytes | 1 | 2024 | 1999 | 0.120 |
Why?
| | Myelin Sheath | 2 | 2008 | 171 | 0.120 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 6 | 0.120 |
Why?
| | Adipocytes, White | 1 | 2015 | 17 | 0.120 |
Why?
| | Leukocytosis | 1 | 2015 | 31 | 0.120 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2016 | 93 | 0.120 |
Why?
| | Pregnancy | 2 | 2023 | 6745 | 0.120 |
Why?
| | Gene Frequency | 1 | 2017 | 521 | 0.120 |
Why?
| | Aged, 80 and over | 7 | 2024 | 7593 | 0.120 |
Why?
| | Hodgkin Disease | 1 | 2017 | 139 | 0.120 |
Why?
| | Pulmonary Diffusing Capacity | 2 | 2013 | 75 | 0.120 |
Why?
| | Dalteparin | 1 | 2014 | 10 | 0.110 |
Why?
| | Computational Biology | 1 | 2019 | 645 | 0.110 |
Why?
| | Incidence | 3 | 2016 | 2792 | 0.110 |
Why?
| | Respiratory Function Tests | 2 | 2013 | 596 | 0.110 |
Why?
| | Harringtonines | 1 | 2013 | 2 | 0.110 |
Why?
| | Transplantation Chimera | 2 | 2012 | 54 | 0.100 |
Why?
| | Pyrazoles | 1 | 2017 | 427 | 0.100 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 433 | 0.100 |
Why?
| | Antilymphocyte Serum | 1 | 2012 | 64 | 0.100 |
Why?
| | Pyridazines | 1 | 2013 | 56 | 0.100 |
Why?
| | Induction Chemotherapy | 2 | 2024 | 74 | 0.100 |
Why?
| | Receptors, CCR5 | 1 | 2012 | 59 | 0.100 |
Why?
| | Graft Survival | 2 | 2025 | 540 | 0.100 |
Why?
| | Bone Marrow | 3 | 2021 | 286 | 0.100 |
Why?
| | Thrombocytopenia | 1 | 2014 | 199 | 0.100 |
Why?
| | Remission Induction | 3 | 2019 | 287 | 0.100 |
Why?
| | Sequence Deletion | 1 | 2012 | 183 | 0.100 |
Why?
| | Neoplasms | 2 | 2019 | 2666 | 0.090 |
Why?
| | Imidazoles | 1 | 2013 | 244 | 0.090 |
Why?
| | Hematopoiesis | 2 | 2010 | 190 | 0.090 |
Why?
| | Ganciclovir | 1 | 2011 | 53 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2014 | 665 | 0.090 |
Why?
| | Fibrinolytic Agents | 1 | 2014 | 275 | 0.090 |
Why?
| | Lung Diseases | 2 | 2011 | 768 | 0.090 |
Why?
| | Caregivers | 1 | 2019 | 872 | 0.090 |
Why?
| | Adipose Tissue | 1 | 2015 | 624 | 0.090 |
Why?
| | Tissue and Organ Procurement | 2 | 2025 | 314 | 0.090 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 363 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2019 | 1115 | 0.090 |
Why?
| | Immunologic Factors | 1 | 2012 | 239 | 0.090 |
Why?
| | Pedigree | 1 | 2012 | 514 | 0.090 |
Why?
| | Length of Stay | 1 | 2016 | 1210 | 0.090 |
Why?
| | Thrombosis | 1 | 2014 | 368 | 0.090 |
Why?
| | Acute Disease | 2 | 2012 | 1008 | 0.080 |
Why?
| | Blood Donors | 1 | 2011 | 103 | 0.080 |
Why?
| | Leukocyte Count | 2 | 2024 | 331 | 0.080 |
Why?
| | Umbilical Cord | 1 | 2010 | 85 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2016 | 1092 | 0.080 |
Why?
| | Neutrophils | 1 | 2015 | 1238 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 558 | 0.080 |
Why?
| | Cell Differentiation | 3 | 2015 | 1979 | 0.080 |
Why?
| | Treatment Failure | 2 | 2009 | 353 | 0.080 |
Why?
| | Polymerase Chain Reaction | 2 | 2024 | 1061 | 0.080 |
Why?
| | Opportunistic Infections | 1 | 2009 | 47 | 0.080 |
Why?
| | Mycosis Fungoides | 1 | 2009 | 61 | 0.080 |
Why?
| | Prednisolone | 1 | 2008 | 83 | 0.070 |
Why?
| | Infant | 4 | 2014 | 9467 | 0.070 |
Why?
| | Comorbidity | 1 | 2013 | 1618 | 0.070 |
Why?
| | Nepal | 4 | 2008 | 29 | 0.070 |
Why?
| | Warfarin | 1 | 2008 | 149 | 0.070 |
Why?
| | Family | 1 | 2012 | 667 | 0.070 |
Why?
| | Child, Preschool | 4 | 2014 | 11097 | 0.070 |
Why?
| | Monitoring, Physiologic | 1 | 2009 | 267 | 0.070 |
Why?
| | Time Factors | 3 | 2025 | 6817 | 0.070 |
Why?
| | Heparin | 1 | 2008 | 259 | 0.070 |
Why?
| | Cell Proliferation | 1 | 2014 | 2482 | 0.070 |
Why?
| | Fatal Outcome | 1 | 2007 | 305 | 0.060 |
Why?
| | Intracranial Hypertension | 1 | 2007 | 38 | 0.060 |
Why?
| | Mice, SCID | 2 | 2019 | 367 | 0.060 |
Why?
| | Interferon-gamma | 1 | 2009 | 790 | 0.060 |
Why?
| | Algorithms | 3 | 2009 | 1702 | 0.060 |
Why?
| | Follow-Up Studies | 5 | 2019 | 5139 | 0.060 |
Why?
| | Thromboembolism | 1 | 2007 | 119 | 0.060 |
Why?
| | Emergency Treatment | 1 | 2007 | 117 | 0.060 |
Why?
| | Risk Assessment | 2 | 2025 | 3439 | 0.060 |
Why?
| | Flow Cytometry | 1 | 2009 | 1185 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 234 | 0.060 |
Why?
| | Mice, Inbred NOD | 2 | 2019 | 601 | 0.060 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2007 | 160 | 0.060 |
Why?
| | Vasodilator Agents | 1 | 2007 | 333 | 0.060 |
Why?
| | Syphilis, Cutaneous | 1 | 2004 | 3 | 0.060 |
Why?
| | Treponema pallidum | 1 | 2004 | 8 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2008 | 498 | 0.060 |
Why?
| | Transplantation, Autologous | 1 | 2005 | 238 | 0.060 |
Why?
| | Survival Rate | 2 | 2019 | 1980 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1950 | 0.050 |
Why?
| | Anticoagulants | 1 | 2008 | 665 | 0.050 |
Why?
| | Anxiety Disorders | 1 | 2007 | 376 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1263 | 0.050 |
Why?
| | Cohort Studies | 2 | 2011 | 5730 | 0.050 |
Why?
| | Cytomegalovirus | 1 | 2023 | 160 | 0.050 |
Why?
| | Drug Interactions | 2 | 2013 | 409 | 0.050 |
Why?
| | Transplant Recipients | 1 | 2023 | 180 | 0.050 |
Why?
| | Sialic Acid Binding Ig-like Lectin 3 | 1 | 2021 | 9 | 0.040 |
Why?
| | Blood Grouping and Crossmatching | 1 | 2021 | 15 | 0.040 |
Why?
| | CD56 Antigen | 1 | 2021 | 36 | 0.040 |
Why?
| | CD3 Complex | 1 | 2021 | 106 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2024 | 720 | 0.040 |
Why?
| | Phenylurea Compounds | 1 | 2020 | 95 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2007 | 2681 | 0.040 |
Why?
| | Tarsal Bones | 1 | 1999 | 13 | 0.040 |
Why?
| | Clubfoot | 1 | 1999 | 6 | 0.040 |
Why?
| | Ultrasonography | 3 | 2008 | 750 | 0.040 |
Why?
| | Lentivirus | 1 | 2019 | 56 | 0.040 |
Why?
| | Benzimidazoles | 1 | 2020 | 169 | 0.040 |
Why?
| | Calcaneus | 1 | 1999 | 31 | 0.040 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 10 | 0.040 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 16 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 2 | 2017 | 920 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 1047 | 0.040 |
Why?
| | Electron Transport Complex II | 1 | 2018 | 26 | 0.040 |
Why?
| | Genes, myc | 1 | 1998 | 48 | 0.040 |
Why?
| | Succinate Dehydrogenase | 1 | 2018 | 49 | 0.040 |
Why?
| | Gene Targeting | 1 | 1998 | 83 | 0.040 |
Why?
| | Tendons | 1 | 1999 | 111 | 0.040 |
Why?
| | Acetazolamide | 2 | 2008 | 26 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 277 | 0.040 |
Why?
| | Oxidative Phosphorylation | 1 | 2018 | 193 | 0.030 |
Why?
| | Machine Learning | 1 | 2022 | 496 | 0.030 |
Why?
| | NADP | 1 | 2016 | 50 | 0.030 |
Why?
| | Genetic Testing | 1 | 2019 | 453 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 1999 | 222 | 0.030 |
Why?
| | Deoxyglucose | 1 | 2016 | 52 | 0.030 |
Why?
| | Sesquiterpenes | 1 | 2016 | 55 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 1060 | 0.030 |
Why?
| | Nitriles | 1 | 2017 | 175 | 0.030 |
Why?
| | Cell Fusion | 1 | 2015 | 51 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2014 | 4206 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 299 | 0.030 |
Why?
| | Prospective Studies | 2 | 2020 | 7598 | 0.030 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 157 | 0.030 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2014 | 14 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2015 | 313 | 0.030 |
Why?
| | Severity of Illness Index | 3 | 2007 | 2838 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 319 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 401 | 0.030 |
Why?
| | Animals | 5 | 2019 | 37011 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 425 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 357 | 0.030 |
Why?
| | Cell Lineage | 1 | 2015 | 346 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2039 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 846 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2014 | 141 | 0.030 |
Why?
| | Pyrimidines | 1 | 2017 | 472 | 0.030 |
Why?
| | Philadelphia Chromosome | 1 | 2013 | 18 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2014 | 286 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2018 | 895 | 0.020 |
Why?
| | Survivors | 1 | 2016 | 489 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 363 | 0.020 |
Why?
| | Gene Expression | 1 | 2017 | 1505 | 0.020 |
Why?
| | Mice | 3 | 2019 | 17843 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1132 | 0.020 |
Why?
| | Cryopreservation | 1 | 2012 | 98 | 0.020 |
Why?
| | Probability | 1 | 2012 | 311 | 0.020 |
Why?
| | DNA | 1 | 1998 | 1460 | 0.020 |
Why?
| | Blood Transfusion | 1 | 2014 | 324 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2011 | 163 | 0.020 |
Why?
| | Hospitalization | 2 | 2014 | 2197 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 1998 | 1507 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1255 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2015 | 2182 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2011 | 233 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2013 | 434 | 0.020 |
Why?
| | Viral Load | 1 | 2011 | 462 | 0.020 |
Why?
| | Apoptosis | 1 | 2018 | 2557 | 0.020 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2008 | 14 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2755 | 0.020 |
Why?
| | Donor Selection | 1 | 2009 | 77 | 0.020 |
Why?
| | Travel | 1 | 2008 | 130 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2095 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 3020 | 0.020 |
Why?
| | Gangrene | 1 | 2007 | 10 | 0.020 |
Why?
| | Bed Rest | 1 | 2007 | 14 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2007 | 41 | 0.020 |
Why?
| | Nifedipine | 1 | 2007 | 30 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2007 | 58 | 0.020 |
Why?
| | Iliac Artery | 1 | 2007 | 56 | 0.020 |
Why?
| | Albuterol | 1 | 2007 | 110 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2014 | 3292 | 0.020 |
Why?
| | Linear Models | 1 | 2008 | 851 | 0.020 |
Why?
| | Sulfones | 1 | 2007 | 110 | 0.020 |
Why?
| | Purines | 1 | 2007 | 176 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2008 | 684 | 0.020 |
Why?
| | Femoral Artery | 1 | 2007 | 178 | 0.020 |
Why?
| | Leg | 1 | 2007 | 223 | 0.010 |
Why?
| | Reference Values | 1 | 2007 | 821 | 0.010 |
Why?
| | Heart Rate | 1 | 2008 | 831 | 0.010 |
Why?
| | Piperazines | 1 | 2007 | 351 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2004 | 191 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5792 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 2064 | 0.010 |
Why?
| | Radiography, Thoracic | 1 | 2004 | 168 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1486 | 0.010 |
Why?
| | Disopyramide | 1 | 1981 | 1 | 0.010 |
Why?
| | Heart Block | 1 | 1981 | 41 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1740 | 0.010 |
Why?
| | Israel | 1 | 1999 | 58 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1999 | 177 | 0.010 |
Why?
| | 3T3 Cells | 1 | 1998 | 163 | 0.010 |
Why?
| | HIV Infections | 1 | 2012 | 2830 | 0.010 |
Why?
| | Pyridines | 1 | 1981 | 508 | 0.010 |
Why?
| | Radiography | 1 | 1999 | 834 | 0.010 |
Why?
| | Reoperation | 1 | 1999 | 569 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 1998 | 379 | 0.010 |
Why?
| | Binding Sites | 1 | 1998 | 1310 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2901 | 0.010 |
Why?
| | Bundle-Branch Block | 1 | 1981 | 31 | 0.000 |
Why?
| | Heart Conduction System | 1 | 1981 | 100 | 0.000 |
Why?
|
|
Gutman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|